Holen Sie sich die Stockscreener-App
10.00
1.38%
-0.14
Vorhandelsmarkt:
9.96
-0.04
-0.40%
Oric Pharmaceuticals Inc Aktie (ORIC) Neueste Nachrichten
Responsive Playbooks and the ORIC Inflection - news.stocktradersdaily.com
Stempoint Capital LP Makes New Investment in Oric Pharmaceuticals, Inc. $ORIC - MarketBeat
Vivo Capital LLC Has $31.74 Million Stock Holdings in Oric Pharmaceuticals, Inc. $ORIC - MarketBeat
Resolute Capital Asset Partners LLC Invests $2.31 Million in Oric Pharmaceuticals, Inc. $ORIC - MarketBeat
Oric Pharmaceuticals (NASDAQ:ORIC) Shares Gap UpShould You Buy? - MarketBeat
ORIC Pharmaceuticals (ORIC) Sees Analyst Rating Update from Wells Fargo | ORIC Stock News - GuruFocus
Oric Pharmaceuticals' (ORIC) Outperform Rating Reaffirmed at Wedbush - MarketBeat
Wedbush Reiterates 'Outperform' Rating for ORIC Pharmaceuticals | ORIC Stock News - GuruFocus
Oric Pharmaceuticals, Inc. Presents Enozertinib Program Update - TradingView
JPMorgan Chase & Co. Raises Stake in Oric Pharmaceuticals, Inc. $ORIC - MarketBeat
ORIC Pharmaceuticals (ORIC) Showcases Promising Phase 1b Trial D - GuruFocus
Transcript : ORIC Pharmaceuticals, Inc.Special Call - marketscreener.com
Fund Flows: Will ORIC Pharmaceuticals Inc stock see PE expansionPortfolio Growth Summary & Growth Focused Investment Plans - BỘ NỘI VỤ
ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and 2L NSCLC Patients with EGFR Exon 20 Mutations at the ESMO Asia Congress 2025 - The Manila Times
ORIC Pharmaceuticals (Nasdaq: ORIC) shares Phase 1b NSCLC data with 67% ORR - Stock Titan
ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust ... - Bakersfield.com
Dir Kunkel Acquires 5,534 Of Oric Pharmaceuticals Inc [ORIC] - TradingView
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
ORIC Pharmaceuticals (Nasdaq: ORIC) Grants 69,200 Options, 11,400 RSUs to New Employees - Stock Titan
Oric Pharmaceuticals (ORIC) Reveals Promising Trial Results for Enozertinib - GuruFocus
Oric Pharmaceuticals (ORIC) Presents Promising Phase 1b Trial Re - GuruFocus
Is ORIC Pharmaceuticals Inc. (4TZ) stock attractive for growth funds2025 Trade Ideas & Daily Profit Focused Stock Screening - Newser
ORIC (Nasdaq: ORIC) shows 35% ORR, 100% DCR in Phase 1b HER2 NSCLC trial - Stock Titan
ORIC Pharmaceuticals, Inc. Announces Data from a Phase 1b Trial of Enozertinib (ORIC-114) at the ESMO Asia Congress 2025 - marketscreener.com
ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and Previously Treated NSCLC Patients with EGFR Atypical Mutations at the ESMO Asia Congress 2025 - The Manila Times
ORIC Pharmaceuticals Reports Promising Preliminary Data for Enozertinib in 1L EGFR PACC Patients with High Response Rates and Favorable Safety Profile - Quiver Quantitative
ORIC Pharmaceuticals (NASDAQ: ORIC) sees 80% ORR, 100% CNS ORR in 1L EGFR PACC NSCLC - Stock Titan
What analysts say about ORIC Pharmaceuticals Inc stockBearish Engulfing Patterns & High Yield Trading Plans - earlytimes.in
Will ORIC Pharmaceuticals Inc. stock see PE expansionProduct Launch & Technical Buy Zone Confirmation - Newser
Why ORIC Pharmaceuticals Inc. (4TZ) stock attracts HNW investorsIPO Watch & Risk Controlled Swing Alerts - Newser
Can ORIC Pharmaceuticals Inc. stock reach $100 price targetQuarterly Trade Review & High Win Rate Trade Tips - Newser
Why analysts recommend ORIC Pharmaceuticals Inc. (4TZ) stockMarket Trend Review & Precise Buy Zone Tips - Newser
Geode Capital Management LLC Trims Stock Position in Oric Pharmaceuticals, Inc. $ORIC - MarketBeat
ORIC Pharmaceuticals Announces Late-Breaking Oral Presentations on Enozertinib (ORIC-114) at ESMO Asia Congress 2025 - Quiver Quantitative
ORIC® Pharmaceuticals Announces Enozertinib (ORIC-114) Late-Breaking Oral Presentations in EGFR Atypical and EGFR exon 20 NSCLC at the ESMO Asia Congress 2025 - The Manila Times
Oric Pharmaceuticals (NASDAQ:ORIC) Shares Down 5.6%Here's Why - MarketBeat
ORIC Pharmaceuticals (ORIC) Stock Analysis Report | Financials & Insights - Benzinga
Top 3 Health Care Stocks That May Rocket Higher In December - Benzinga
Can ORIC Pharmaceuticals Inc. stock deliver sustainable ROEJuly 2025 Review & Consistent Income Trade Ideas - Newser
Why ORIC Pharmaceuticals Inc. stock could rally in 2025Take Profit & Daily Growth Stock Investment Tips - Newser
Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Is ORIC Pharmaceuticals Inc. (4TZ) stock positioned for secular growth2025 Technical Overview & Stepwise Trade Signal Implementation - Newser
Why ORIC Pharmaceuticals Inc. (4TZ) stock benefits from AI revolutionRate Hike & AI Driven Stock Reports - Newser
ORIC Pharmaceuticals (ORIC) Valuation Check as New Phase 1b Enozertinib Lung Cancer Data Approaches - Yahoo Finance
What MACD trends signal for ORIC Pharmaceuticals Inc. (4TZ) stock2025 Performance Recap & Detailed Earnings Play Strategies - Newser
How buyback programs support ORIC Pharmaceuticals Inc. (4TZ) stock2025 Key Lessons & AI Driven Stock Price Forecasts - Newser
ORIC® Pharmaceuticals Announces Enozertinib (ORIC-114) Poster Presentation in HER2 exon 20 NSCLC at the ESMO Asia Congress 2025 - The Manila Times
ORIC Pharmaceuticals (Nasdaq: ORIC) to share Phase 1b HER2 exon 20 NSCLC data at ESMO Asia 2025 - Stock Titan
Bull Bear: How strong is ORIC Pharmaceuticals Inc. stock revenue growthJuly 2025 Sector Moves & Safe Capital Growth Tips - BỘ NỘI VỤ
Franklin Resources Inc. Raises Position in Oric Pharmaceuticals, Inc. $ORIC - Defense World
How strong is ORIC Pharmaceuticals Inc. stock revenue growthJuly 2025 Selloffs & Capital Protection Trade Alerts - BỘ NỘI VỤ
Understanding the Setup: (ORIC) and Scalable Risk - news.stocktradersdaily.com
Technical Heatmap Flags Shrydus Industries Limited for WatchEarnings Revision Updates & Big Profit Low Trading - earlytimes.in
ORIC Pharmaceuticals, Inc. (ORIC) Secures $125M to Advance ORIC-944 Phase 3 Trials - MSN
How New ORIC-944 Trial Results and Earnings Update Will Impact ORIC Pharmaceuticals (ORIC) Investors - Yahoo Finance
ORIC® Pharmaceuticals to Participate in the 8th Annual Evercore Healthcare Conference - The Manila Times
Oric Pharmaceuticals (NASDAQ:ORIC) Rating Lowered to Sell at Wall Street Zen - MarketBeat
Pattern Scan Adds SVP Global Textiles Limited to WatchlistSwing Trading Ideas & Fast Growing Investment Ideas - earlytimes.in
0.45%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):